Mechanisms of Action of GLP-1 and GIP

From incretin physiology to GLP-1/GIP receptor agonists

Today’s goals

  1. Explain the incretin effect
  2. Explain the differences between GLP-1 and GIP in secretion and degradation (DPP-4)
  3. Explain the flow receptor → cAMP → insulin secretion, and why it is glucose-dependent
  4. Explain the differences between GLP-1 and GIP actions in the islets and outside the pancreas
  5. Explain the design rationale of GLP-1RAs and tirzepatide

1. The incretin effect

Same blood glucose, different insulin

  • Oral glucose vs intravenous glucose reproducing the same glucose profile
  • More insulin secretion with oral glucose → this difference is the incretin effect
  • 50–70% of postprandial insulin secretion in healthy people
  • Greatly reduced in type 2 diabetes
    • Response to GIP reduced, response to GLP-1 relatively preserved

The two incretins

GIP GLP-1
Secreting cell K-cells L-cells
Site Duodenum, upper jejunum Ileum, colon
Precursor proGIP Proglucagon (PC1/3)
Length 42 aa 30–31 aa
Half-life 5–7 min 1–2 min

2. Secretion and degradation

Differential processing of proglucagon

flowchart LR
  P["Proglucagon"] -->|"Pancreatic α-cells / PC2"| A["Glucagon"]
  P -->|"L-cells, brain NTS / PC1/3"| B["GLP-1, GLP-2<br/>Oxyntomodulin"]

DPP-4: cuts the two N-terminal residues

  • Second residue from the N-terminus is Ala → DPP-4 substrate
    • GLP-1: H-A-E-G-… → GLP-1(9-36)
    • GIP: Y-A-E-G-… → GIP(3-42)
  • The N-terminus that is cut off = the part that activates the receptor → almost inactive
  • Only about 10–15% of active GLP-1 reaches the systemic circulation

3. Receptors and signaling

Class B1 GPCRs

  • GLP-1R, GIPR: class B1 GPCRs (secretin receptor family)
  • Two-step binding: C-terminal part binds the extracellular domain → N-terminal part enters the transmembrane core and activates
  • Main pathway: Gαs → AC → cAMP → PKA / Epac2

Triggering and amplification

flowchart LR
  G["Blood glucose↑"] --> ATP["ATP/ADP↑"] --> K["K_ATP closure"] --> D["Depolarization"] --> Ca["Ca²⁺ influx"] --> Ins["Insulin release"]
  SU["SU drugs"] -.->|"regardless of glucose"| K
  Inc["GLP-1 / GIP<br/>→ cAMP"] ==>|"amplify"| Ins

  • Incretins = amplification only → nothing to amplify during hypoglycemia → glucose-dependent
  • SU drugs = pull the trigger directly → risk of hypoglycemia

4. The islets

Opposite actions on α-cells

GLP-1 GIP
β-cells Insulin↑ (glucose-dependent) Insulin↑ (glucose-dependent)
α-cells Glucagon↓ (via δ-cells, β-cells) Glucagon↑ (direct, during hypoglycemia)
  • GIP = a bidirectional hormone that uses insulin and glucagon selectively according to blood glucose
  • β-cell proliferative action: mainly rodent data

5. Extrapancreatic actions

Actions by organ

Organ GLP-1 GIP
Brain Appetite↓ (hypothalamus, brainstem), nausea Appetite↓? Nausea↓?
Stomach Delayed gastric emptying (attenuates with sustained stimulation) —
Fat — Lipid uptake↑ (lipid buffering)
Heart, kidney MACE↓ (SELECT), kidney events↓ (FLOW) Much unknown
Bone — Bone resorption↓

Appetite suppression in the brain

  • Routes: vagal afferents / circumventricular organs (area postrema, arcuate nucleus) / GLP-1 neurons in the brain
  • Arcuate nucleus: POMC/CART↑, NPY/AgRP↓
  • Area postrema, NTS: satiety + nausea, vomiting
  • GIPR (GABA neurons in the area postrema) may alleviate nausea (animals)

6. Application to drugs

Two approaches

  • DPP-4 inhibitors: block the enzyme → endogenous GLP-1/GIP 2–3-fold within the physiological range
  • GLP-1RAs: analogues that are not destroyed → sustained stimulation at pharmacological doses
Drug Trick Half-life
Exenatide exendin-4 (Gly2) 2.4 h
Liraglutide C16 fatty acid → albumin binding 13 h
Semaglutide Aib8 + C18 fatty diacid about 1 week
Tirzepatide GIP-based + Aib + C20 fatty diacid about 5 days

Tirzepatide

  • Imbalanced: GIPR ≈ native GIP; GLP-1R about 1/5 of native GLP-1
  • cAMP bias at GLP-1R (β-arrestin recruitment↓, internalization↓)
  • Weight loss: SURMOUNT-1 −20.9% (72 weeks); superior to semaglutide 2.4 mg in SURMOUNT-5

The GIP paradox

  • Both agonism (tirzepatide) and antagonism (MariTide) reduce weight↓ when combined with GLP-1R agonism
  • Hypotheses
    • Sustained agonism → desensitization → functional antagonism
    • Agonists and antagonists act in different tissues
  • Unresolved —— treat it as a comparison of hypotheses

Side effects

  • Gastrointestinal symptoms (most common) → start low, escalate every 4 weeks
  • Gallstones, pancreatitis, hypoglycemia when combined
  • Loss of lean mass, weight regain after discontinuation
  • Delayed gastric emptying → perioperative aspiration risk

Summary

  • The incretin effect is carried by GIP (K-cells) and GLP-1 (L-cells)
  • Inactivated by DPP-4 within minutes → drugs are long-acting through DPP-4 resistance + albumin binding
  • Amplification via cAMP → glucose-dependent → rarely causes hypoglycemia on its own
  • α-cells: GLP-1 glucagon↓, GIP glucagon↑
  • Weight loss is mainly via the brain. The role of GIP (the paradox) is still under investigation